CD27 signalling has been found to be necessary to generate robust cytotoxic T cells,46,47 so CD27 agonists might further improve anti-PD-1 or CTLA-4 immunotherapy in cases where tumour-specific T cells are suboptimal. Here, CD27 is linked to neoplasm.